ArticleFrontiers in immunology2025
The diagnostic and prognostic role of novel biomarkers in anti-neutrophil cytoplasmic antibody-associated vasculitis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of the systemic immune-inflammation index (SII) in rheumatic diseases.Frontiers in immunology · 2026Pooled it
- Inflammatory blood count ratios discriminate disease activity and remain persistently elevated during glucocorticoid-free remission in ANCA-associated vasculitis.Clinical and experimental medicine · 2026Article
- Guideline-recommended inflammatory testing in symptomatic dermographism: a real-world study.Frontiers in immunology · 2026Article
- Peripheral blood inflammatory indices across thyroid functional states in Graves' disease: associations with liver biochemical abnormalities and hyperthyroid relapse.Frontiers in endocrinology · 2026Article
- The predictive value of baseline systemic inflammation response index and systemic immune-inflammation index for the risk of infection within 6 months following initial immunosuppressive treatment in patients with ANCA-associated vasculitis.Frontiers in immunology · 2026Article
- CBC‑derived inflammatory indices for rheumatoid arthritis diagnosis and activity assessment: differential performance by serostatus.Frontiers in immunology · 2026Article
- Inflammatory index-based nomogram for risk stratification of erectile dysfunction: a cross-sectional study with dual-cohort validation and mendelian randomization analysis.Translational andrology and urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: ANCA-associated vasculitis (AAV) is a group of autoimmune diseases characterized by small vessel inflammation, diagnosed primarily through clinical features, histopathology, and ANCA testing. Novel biomarkers derived from routine blood counts, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), may support disease assessment. This study evaluated their utility in distinguishing AAV patients, reflecting disease activity, and predicting prognosis. Methods: In this retrospective case-control study, 65 AAV patients and 65 age- and sex-matched healthy controls were enrolled. AAV diagnosis adhered to the 2012 Chapel Hill Consensus and the American College of Rheumatology 1990 criteria. NLR, PLR, MLR, SII, and SIRI were calculated from complete blood counts. Disease activity (Birmingham Vasculitis Activity Score, BVAS), extent (Disease Extent Index, DEI), damage (Vasculitis Damage Index, VDI), and prognosis (Five-Factor Score, FFS 2009) were assessed. Statistical analyses included Mann-Whitney U tests, Spearman correlations, and receiver operating characteristic (ROC) curves to evaluate discriminatory and predictive capacities. Results: AAV patients exhibited significantly higher NLR (6.94 ± 0.76 vs. 1.88 ± 0.08), PLR (242.44 ± 23.09 vs. 125.97 ± 4.34), MLR (0.44 ± 0.03 vs. 0.20 ± 0.01), SII (1813.71 ± 221.85 vs. 446.62 ± 22.40), and SIRI (3.19 ± 0.31 vs. 0.72 ± 0.06) compared to controls (all P < 0.001). ROC analysis showed strong discriminatory power, with SIRI (AUC = 0.902) and NLR (AUC = 0.885) performing best. NLR, PLR, SII, and SIRI correlated positively with BVAS (rs = 0.325-0.356, Conclusions: NLR, PLR, MLR, SII, and SIRI effectively distinguish AAV patients from controls and reflect disease activity, extent, and prognosis. While not standalone diagnostic tools, these markers offer valuable support to standard AAV assessment, particularly in challenging cases. Their accessibility suggests potential for enhancing clinical management, pending validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.